Comparison of age-related macular degeneration treatments trials (CATT) reported the results of the first year: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Bevacizumab is a monoclonal antibody (MAb) and full-length antiVEGF antibody that successfully prevents binding of all the biologically active isoforms of VEGF to the receptor. Ranibizumab is a isolated antigenbinding fragment (Fab) from bevacizumab using recombinant genetic techniques. Ranibizumab has been clinically evaluated in 4 Phase I/II studies. The cost of Avastin is
50 per dose compared with
2000 per dose for Ranibizumab. If Avastin could improve vision and macular anatomy, then it would not only be clinically superior to Ranibizumab. The CATT data support the continued global use of intravitreal bevacizumab as an effective, low-cost alternative to ranibizumab, particularly for patients paying all costs out of pocket.

Citation： 黎晓新. Inspiration from comparison of age-related macular degeneration treatments trials. Chinese Journal of Ocular Fundus Diseases, 2011, 27(3): 205-206. doi: Copy